A review of PCSK9 monoclonal antibodies in Australia has delivered a consensus on the groups of people who would benefit from LDL-cholesterol lowering and a subsequent reduced risk for cardiovascular events. However to be implemented it would require a costly expansion of PBS indications, according to the expert opinion of 10 cardiologists . “Broader access ...
Already a member?
Enter your email to keep reading.